Zika virus infection

Zika virus infection
Cramunhao · CC BY-SA 4.0 · source
Name	Zika virus
Virus group	Flavivirus
Family	Flaviviridae
Genus	Flavivirus
Species	Zika virus

Zika virus infection Zika virus infection is an arboviral disease caused by a mosquito-borne flavivirus within the Flaviviridae family, first identified in the Zika Forest of Uganda in 1947. It attracted global attention during outbreaks across the Pacific Ocean and the Americas in the 2010s when associations with congenital anomalies and neurological syndromes were reported. The illness ranges from asymptomatic infection to fever, rash, arthralgia and severe neurodevelopmental consequences in fetuses and neonates. Research into virus structure, transmission dynamics, immunopathology and public health responses has involved numerous international organizations and scientific collaborations.

Virology and pathogenesis

Zika virus belongs to the Flavivirus group alongside Dengue fever, Yellow fever, West Nile virus, Japanese encephalitis virus and Tick-borne encephalitis virus. Its genome is a single-stranded positive-sense RNA that encodes structural proteins (capsid, premembrane/membrane, envelope) and nonstructural proteins (NS1–NS5), with NS5 functioning as an RNA-dependent RNA polymerase and methyltransferase; studies from laboratories at Centers for Disease Control and Prevention and Pasteur Institute detailed these molecular features. Viral entry into host cells involves receptor-mediated endocytosis with interactions reported for attachment factors found on neural progenitor cells; investigations at Howard Hughes Medical Institute and Johns Hopkins University linked viral tropism to placental and fetal neurotropism, contributing to microcephaly. Host immune responses implicate innate sensors such as RIG-I and MDA5 and adaptive responses including neutralizing antibodies that cross-react with related flaviviruses, complicating serodiagnosis; work by teams at World Health Organization and National Institutes of Health explored antibody-dependent enhancement observed with Dengue fever in co-endemic regions.

Transmission

Primary transmission occurs via the bite of infected female mosquitoes, principally Aedes aegypti and Aedes albopictus, vectors also responsible for spread of Dengue fever and Chikungunya. Outbreaks in French Polynesia, Brazil, Colombia, Puerto Rico and Florida emphasized urban and peri-urban transmission driven by vector ecology and human mobility; investigations involved surveillance by Pan American Health Organization and national public health institutes. Non-vector routes include vertical transmission during pregnancy resulting in congenital infection and transplacental passage described in cases linked to Americas outbreak reports. Sexual transmission has been documented with viral RNA detected in semen and rare documented cases linked to male-to-female and male-to-male transmission; blood transfusion and organ transplantation transmission have been reported and led to screening recommendations by agencies such as Food and Drug Administration.

Clinical manifestations

Most infections are asymptomatic; symptomatic illness typically presents with sudden onset low-grade fever, maculopapular rash, non-purulent conjunctivitis and arthralgia, often accompanied by myalgia and headache, as described in outbreak reports from Micronesia and Samoa. Complications include congenital Zika syndrome characterized by severe microcephaly with partially collapsed skull, intracranial calcifications, ocular abnormalities, arthrogryposis and hypertonia; case series from Brazil and cohort studies at Centers for Disease Control and Prevention established these links. Neurological complications in adults include Guillain–Barré syndrome, acute disseminated encephalomyelitis and meningoencephalitis; epidemiological associations were reported following outbreaks in French Polynesia and El Salvador. Risk factors for severe outcomes include first-trimester maternal infection and prior exposure to related flaviviruses as investigated by researchers at Imperial College London and Karolinska Institutet.

Diagnosis

Laboratory confirmation relies on detection of viral RNA by reverse transcription polymerase chain reaction (RT-PCR) in serum, urine, semen or cerebrospinal fluid during the acute phase; protocols and validation studies were published by World Health Organization and Centers for Disease Control and Prevention. Serologic testing detects Zika virus-specific IgM and neutralizing antibodies, but interpretation is complicated by cross-reactivity with antibodies to Dengue fever and prior vaccination against Yellow fever or infection with related flaviviruses; approaches such as plaque reduction neutralization tests were refined at institutions including Pasteur Institute to improve specificity. Imaging modalities, including cranial ultrasound and MRI, are essential for prenatal assessment of fetal brain anomalies; obstetric practice guidelines from professional bodies like American College of Obstetricians and Gynecologists informed surveillance strategies.

Treatment and management

There is no specific antiviral therapy approved for Zika virus infection; management is supportive and symptomatic using analgesics and hydration, with avoidance of nonsteroidal anti-inflammatory drugs until dengue is excluded per guidance from World Health Organization and national agencies. Management of congenital Zika syndrome requires multidisciplinary long-term care including neurology, ophthalmology, orthopedics and developmental pediatrics; specialized centers at academic hospitals such as Johns Hopkins Hospital and Mayo Clinic developed care pathways. Investigational therapeutics, monoclonal antibodies and vaccine candidates progressed through preclinical and clinical trials supported by collaborations among National Institutes of Health, pharmaceutical companies and academic consortia; examples include RNA-based and inactivated vaccine platforms evaluated in trials overseen by regulatory agencies including European Medicines Agency.

Prevention and public health measures

Prevention emphasizes vector control strategies targeting Aedes aegypti breeding sites, insecticide resistance monitoring, community engagement and novel interventions such as Wolbachia-infected mosquito releases and genetically modified mosquitoes trialed in field studies coordinated by organizations like Bill & Melinda Gates Foundation and World Mosquito Program. Travel advisories and screening policies during outbreaks were issued by Centers for Disease Control and Prevention and national ministries of health to protect pregnant travelers and guide reproductive counseling. Blood donation screening and laboratory safety measures were implemented by institutions including Food and Drug Administration and national blood services. International cooperative surveillance, research and response efforts were coordinated by World Health Organization, Pan American Health Organization and research networks to mitigate future outbreaks and develop vaccines and diagnostics.

Category:Arthropod-borne viral diseases